SemiCab Partners with RoaDo to Drive Revenue Growth and Expand Carrier Fleet Access

(NASDAQ:RIME), New Strategic Partnership Unlocks Expanded Carrier Network Through RoaDo Integration Fort Lauderdale, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (NASDAQ: RIME), a leading AI logistics provider, today announced that its subsidiary SemiCab Holdings, LLC (“SemiCab”) has entered into a strategic partnership with Hicetane Logistics Innovations Pvt. Ltd., an India-based shipping technology […]

SOLOWIN to Jointly Launch US$100M Bitcoin Quantitative Fund with Antalpha

(NASDAQ:SWIN), Strategic collaboration targets US$100M in assets under management through algorithmic Bitcoin trading HONG KONG, Aug. 13, 2025 (GLOBE NEWSWIRE) — SOLOWIN HOLDINGS (NASDAQ: SWIN) (“Solowin” or the “Company”), a leading financial services firm providing comprehensive solutions across traditional and digital assets, today announced its plan to launch a joint Bitcoin quantitative fund with Antalpha,

Amaero Publishes Financial and Corporate Update

(AUST:3DA),(AUST:3DA.AX),(OTC US:AMROF),(Other OTC:AMROF), MCDONALD, Tenn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Amaero Ltd (ASX:3DA) (OTCQB: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value C103, refractory alloy, and titanium powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, today provides a financial and commercial update

Diamond Equity Research Releases Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST)

(NasdaqGM:BHST), New York, Aug. 13, 2025 (GLOBE NEWSWIRE) — Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST). The update note includes detailed information on BioHarvest Sciences' financial results, operational updates, business model, management commentary, valuation, and

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

(NASDAQ:CTMX), – The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 – – The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE

PodcastOne (NASDAQ: PODC) Reports Record Q1 Fiscal 2026 Financial Results

(NASDAQ:PODC), Q1 Fiscal 2026 Revenue: ~$15.0 Million (Record) Q1 Fiscal 2026 Adjusted EBITDA*: ~$0.6 Million Fiscal 2026 Guidance: Revenue: $55-60 Million, Adjusted EBITDA*: $3-5 Million LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) — PodcastOne (Nasdaq: PODC), a leading publisher and podcast sales network, announced today its operating results for the first fiscal quarter (“Q1 Fiscal

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D(TM) Fusion Imaging for Interventional Cardiology

(NASDAQ:BCDA), SUNNYVALE, Calif. and UTRECHT, Netherlands, Aug. 13, 2025 (GLOBE NEWSWIRE) — BioCardia(R), Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, today announce that they have entered into

Dave Inc. Expands Share Repurchase Authorization to $125 Million Following Strong Buyback Activity

(NasdaqGM:DAVE), Los Angeles, Aug. 13, 2025 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE) today announced that its Board of Directors has approved an increase in the Company's share repurchase authorization to $125 million, which replaces the previous $50 million authorization announced on March 10, 2025. Since Dave reported its second quarter

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

(NASDAQ:OVID), Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the Company from a non-pipeline asset OV4071, the first ever oral KCC2 direct activator, is completing

Infinidat Wins 2025 FMS Award for Most Innovative AI Application with RAG Reference Architecture on the InfiniBox(R) G4 Platform

WALTHAM, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) — Infinidat, a leading provider of enterprise storage solutions, today announced that Infinidat's Retrieval-Augmented Generation (RAG) reference architecture, operating on the new-generation InfiniBox(R) G4 family of enterprise storage solutions, has been awarded a “Best of Show” award for the “Most Innovative Artificial Intelligence (AI) Application“ at the 2025

Scroll to Top